Claims for Patent: 9,867,799

Summary for Patent: 9,867,799

Title:	Diethyl-[6-(4-hydroxycarbamoyl-phenyl-carbamoyloxy-methyl)-naphthalen-2-yl-methyl]-ammonium chloride for use in the treatment of muscular dystrophy
Abstract:	The present invention relates to a method for treating muscular dystrophy which comprises administering diethyl-[6-(4-hydroxycarbamoyl-phenyl-carbamoyloxy-methyl)-naphthalen-2-yl-methyl]-ammonium chloride or other pharmaceutically acceptable salts and/or solvates thereof to a patient in need of such a treatment. The invention further relates to a method for treating muscular dystrophy which comprises administering diethyl-[6-(4-hydroxycarbamoyl-phenyl-carbamoyloxy-methyl)-naphthalen-2-yl-methyl]-ammonium chloride or other pharmaceutically acceptable salts and/or solvates thereof in combination with one or more additional anti-inflammatory active agents to a patient in need of such a treatment.
Inventor(s):	Saccone Valentina, Consalvi Silvia, Puri Pier Lorenzo, Mascagni Paolo
Assignee:	ITALFARMACO S.P.A.
Application Number:	US15208957
Patent Claims:	2. The method according to claim 1 , wherein said additional anti-inflammatory agent is a steroid.3. The method according to claim 2 , wherein said steroid is selected from the group consisting of prednisolone claim 2 , prednisone claim 2 , deflazacort claim 2 , hydrocortisone claim 2 , methylprednisolone claim 2 , dexamethasone claim 2 , betamethasone claim 2 , triamcinolone claim 2 , beclometasone claim 2 , fludrocortisone acetate claim 2 , and deoxycorticosterone acetate.4. The method according to claim 1 , wherein said diethyl-[6-(4-hydroxycarbamoyl-phenylcarbamoyloxymethyl)-naphthalen-2-yl-methyl]-ammonium chloride claim 1 , or the pharmaceutically acceptable salts and/or solvates thereof claim 1 , and said additional anti-inflammatory agent are administered simultaneously claim 1 , separately claim 1 , or sequentially.5. The method according to claim 1 , wherein said muscular dystrophy is Duchenne muscular dystrophy.6. The method according to claim 1 , wherein the administration to the patient is on a daily basis.7. The method according to claim 1 , wherein said diethyl-[6-(4-hydroxycarbamoyl-phenylcarbamoyloxymethyl)-naphthalen-2-yl-methyl]-ammonium chloride claim 1 , or the pharmaceutically acceptable salts and/or solvates thereof is administered in an amount ranging from 0.5 to 15 mg/kg/day.8. The method according to claim 1 , wherein said patient is a child.9. The method according to claim 8 , wherein said diethyl-[6-(4-hydroxycarbamoyl-phenylcarbamoyloxymethyl)-naphthalen-2-yl-methyl]-ammonium chloride claim 8 , or the pharmaceutically acceptable salts and/or solvates thereof is administered in an amount ranging from 1 to 10 mg/kg/day.10. The method according to claim 1 , wherein said diethyl-[6-(4-hydroxycarbamoyl-phenylcarbamoyloxymethyl)-naphthalen-2-yl-methyl]-ammonium chloride claim 1 , or the pharmaceutically acceptable salts and/or solvates thereof is administered in the form of a pharmaceutical composition comprising the same together with at least one physiologically acceptable excipient.11. The method according to claim 10 , wherein said pharmaceutical composition is administered by oral claim 10 , sublingual claim 10 , rectal claim 10 , intravascular claim 10 , intravenous claim 10 , or subcutaneous route.12. The method according to claim 11 , wherein said pharmaceutical composition is in a solid or a liquid form.13. The method according to claim 12 , wherein said solid form is selected from the group consisting of powder claim 12 , tablet claim 12 , granulate claim 12 , aggregate claim 12 , compressed pill claim 12 , coated pill claim 12 , hard gelatin capsule claim 12 , and gelatin capsule.14. The method according to claim 12 , wherein said liquid form is a suspension or a syrup.15. The method according to claim 1 , wherein said diethyl-[6-(4-hydroxycarbamoyl-phenylcarbamoyloxymethyl)-naphthalen-2-yl-methyl]-ammonium chloride is in a monohydrate form.16. The method according to claim 1 , wherein said diethyl-[6-(4-hydroxycarbamoyl-phenylcarbamoyloxymethyl)-naphthalen-2-yl-methyl]-ammonium chloride is in a crystal form.